[1]贺春艳,吴月明.非小细胞肺癌患者缺氧诱导因子、血管内皮细胞生长因子表达水平及其临床意义[J].陕西医学杂志,2022,51(4):503-506.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.028]
　HE Chunyan,WU Yueming.Expression levels of HIF-2α and VEGF in NSCLC patients and their clinical significance[J].,2022,51(4):503-506.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.028]
点击复制

非小细胞肺癌患者缺氧诱导因子、血管内皮细胞生长因子表达水平及其临床意义
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年4期
页码:
503-506
栏目:
临床病理
出版日期:
2022-04-05

文章信息/Info

Title:
Expression levels of HIF-2α and VEGF in NSCLC patients and their clinical significance
作者:
贺春艳; 吴月明
(锦州医科大学附属第三医院肿瘤二科,辽宁 锦州 121001)
Author(s):
HE Chunyan; WU Yueming
(Department of Oncology, the Third Affiliated Hospital of Jinzhou Medical University,Jinzhou 121001,China)
关键词:
非小细胞肺癌;  缺氧诱导因子;  血管内皮细胞生长因子;  非小细胞肺癌组织标本;  癌旁组织标本;  临床病理
Keywords:
Non-small cell lung cancer;  Hypoxia inducible factor;  Vascular endothelial cell growth factor;  NSCLC tissue specimen;  Paracancer tissue specimen;  Clinicopathology
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2022.04.028
文献标志码:
A
摘要:
目的:探讨非小细胞肺癌(NSCLC)患者缺氧诱导因子(HIF)-2α、血管内皮细胞生长因子(VEGF)表达水平及临床意义。方法: 选择接诊的86例NSCLC患者,收集所有患者的NSCLC组织标本及癌旁组织标本。比较NSCLC组织和癌旁组织,不同临床病理NSCLC组织中HIF-2α、VEGF阳性表达率,并分析HIF-2α和VEGF之间的相关性。结果: NSCLC组织中HIF-2α、VEGF阳性表达率分别为65.12%、69.77%,均明显高于癌旁组织的10.47%、16.28%,比较差异有统计学意义(均P<0.05); 肿瘤直径≥5 cm、TNM分期Ⅲ-Ⅳ期、低分化、有淋巴结转移患者的HIF-2α、VEGF阳性表达率明显高于肿瘤直径<5 cm、TNM分期Ⅰ-Ⅱ期、中高分化、无淋巴结转移患者,比较差异有统计学意义(均P<0.05); 经过Spearman等级相关性分析显示,HIF-2α和VEGF之间呈正相关(P<0.05)。结论: NSCLC组织中HIF-2α、VEGF表达明显升高,且和肿瘤直径、TNM分期、分化程度、淋巴结转移之间密切相关。
Abstract:
Objective:To study the expression levels of hypoxia-inducible factor(HIF)-2α and vascular endothelial cell growth factor(VEGF)in patients with non-small cell lung cancer(NSCLC)and their clinical significance.Methods:A total of 86 NSCLC patients were selected.The NSCLC tissue specimens and paracancer tissue specimens of all patients were collected.The positive expression rates of HIF-2α and VEGF in NSCLC tissues,paracancer tissues and different clinicopathological NSCLC tissues were compared.The correlation between HIF-2α and VEGF was analyzed.Results:The positive expression rates of HIF-2α and VEGF in SCLC tissues were 65.12% and 69.77%,which were significantly higher than those in adjacent tissues(10.47% and 16.28%),with statistical significance(all P<0.05).The positive expression rates of HIF-2α and VEGF in patients with tumor diameter ≥5 cm,TNM stage Ⅲ to Ⅳ,low differentiation and lymph node metastasis were significantly higher than those in patients with tumor diameter < 5 cm,TNM stage Ⅰ to Ⅱ,medium-high differentiation and no lymph node metastasis(all P<0.05).Spearman correlation analysis showed that HIF-2α was positively correlated with VEGF(P<0.05).Conclusion:The expression levels of HIF-2α and VEGF are significantly increased in NSCLC tissues,and are closely related to tumor diameter,TNM stage,degree of differentiation,and lymph node metastasis.

参考文献/References:

[1] 张美娟.非小细胞肺癌患者发病危险因素的Logistic回归分析[J].中国卫生统计,2020,37(3):462-464.
[2] 彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851-854.
[3] 周文婷.HIF-1活性调控机制的研究进展[J].生理科学进展,2020,51(6):443-448.
[4] 朱 培,唐梦燕,闫东梅.HIF-1α及其相关信号转导通路在疾病中的研究进展[J].中国免疫学杂志,2020,36(13):1650-1653,1657.
[5] 蒋 峰,柳小芳,高艺文,等.解毒散结方联合化疗治疗晚期胃癌疗效及对患者血管内皮生长因子和受体的影响[J].陕西中医,2021,42(5):582-585.
[6] 中华人民共和国卫生部.原发性肺癌诊疗规范(2011年版)[J].中国肺癌杂志,2012,15(12):677-688.
[7] Duma N,Santana-Davila R,Molina JR.Non-small cell lung cancer:Epidemiology,screening,diagnosis,and treatment[J].Mayo Clin Proc,2019,94(8):1623-1640.
[8] Arbour KC,Riely GJ.Systemic therapy for locally advanced and metastatic non-small cell lung cancer:A review[J].JAMA,2019,322(8):764-774.
[9] 黄思佳,邱旭东,李文彦,等.肿瘤微环境中的细胞调控网络及促瘤机制[J].生命科学,2020,32(4):315-324.
[10] Hayashi Y,Yokota A,Harada H,et al.Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1alpha in cancer[J].Cancer Sci,2019,110(5):1510-1517.
[11] 谢江涛,冯乐宵,王世锋,等.常氧及低氧条件下SHG-44胶质瘤细胞中活性氧及低氧诱导因子-1α的表达及意义[J].陕西医学杂志,2021,50(11):1345-1348.
[12] 顾 霞,赵 敏,王平义,等.低氧诱导因子1α与低氧相关疾病信号通路的关系[J].中国组织工程研究,2021,25(8):1284-1289.
[13] 马金华,马金兰,王丽娟,等.青海地区藏族、汉族HIF-2α基因单核苷酸多态性与胃癌易感性的相关性研究[J].中国医药导报,2019,16(12):9-12,22.
[14] Susen RM,Bauer R,Olesch C,et al.Macrophage HIF-2alpha regulates tumor-suppressive spint1 in the tumor microenvironment[J].Mol Carcinog,2019,58(11):2127-2138.
[15] 李建丽,李永梅,康鸿斌,等.ANXA2、STAT3、VEGF在乳腺癌中的表达及与肿瘤转移的关系[J].癌症进展,2020,18(3):241-244.
[16] 于韦韦,王 海,张 捷,等.骨桥蛋白、基质金属蛋白酶2和血管内皮生长因子在胃癌组织中的表达及其预后价值[J].肿瘤研究与临床,2019,31(6):390-394.
[17] Albadari N,Deng S,Li W.The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy[J].Expert Opin Drug Discov,2019,14(7):667-682.
[18] 刘艳梅,杨 琪,王赛赛,等.HIF-1α和HIF-2α蛋白在宫颈癌中的表达及与预后的关系[J].浙江医学,2020,42(2):105-108,113.
[19] 雷 芸,闫春良,薛旗山,等.VEGF、VEGFR在NSCLC组织中的表达及临床意义[J].癌症进展,2019,17(13):1573-1575.
[20] Jonna S,Subramaniam DS.Molecular diagnostics and targeted therapies in non-small cell lung cancer(NSCLC):An update[J].Discov Med,2019,27(148):167-170.
[21] 窦 妍,姜 达.小分子抗血管生成药物在非小细胞肺癌中的研究进展[J].中国肺癌杂志,2021,24(1):56-62.

相似文献/References:

[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
　PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(4):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[3]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
　YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(4):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[4]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[5]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
　SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(4):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
　CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(4):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[8]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
　CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(4):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[9]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
　CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(4):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[10]梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
　LIANG Lele,WANG Peng,LIU Junxia,et al.Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer[J].,2021,50(4):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]

更新日期/Last Update: 2022-04-07